adMare Industry Builder Series

adMare Industry Builder Series Featuring Dr. Clifford Woolf: Cell Versus Target-based Screening for Novel Analgesics.

On October 18th at 12 PM ET, Dr. Clifford Woolf will join adMare's Industry Builder Series to discuss Cell Versus Target-based Screening for Novel Analgesics.

Dr. Woolf is the Director of the F.M. Kirby Neurobiology Center and the Neurobiology Program at Boston Children's Hospital, and he is a faculty member of the Harvard Stem Cell Institute and the Department of Neurobiology at Harvard Medical School.

Dr. Woolf aims to reboot drug discovery to find a new way to treat pain and neurodegenerative diseases: effectively and responsibly.

During his impressive career, Dr. Woolf founded 5 successful biotech companies: Solace Pharmaceuticals, FerruMax Pharmaceuticals, Quartet Medicine, QurAlis, and Nocion Therapeutics. In addition, he counsels many of the top pharmaceutical companies' neuroscience departments. 

The generation of human neurons from patient and healthy volunteer iPSC lines enables high content phenotypic screening, including for nociceptor-selective analgesics and neuroprotectants to prevent neuropathy. During this Industry Builder event, Dr. Woolf will discuss the advantages of this novel drug discovery approach over and in combination with traditional target-based screening.

Who is Dr. Clifford J. Woolf ? 
DR. CLIFFORD J. WOOLF was born in South Africa, where he earned his MB, BCh, and Ph.D. degrees. He then moved to London and became a Professor of Neurobiology at University College London. In 1997 he was recruited by the Massachusetts General Hospital and Harvard Medical School to serve as the Richard J. Kitz Professor of Anesthesiology Research. In 2010 he was named director of the F. M. Kirby Neurobiology Center at Boston Children’s Hospital and became a Professor of Neurology and Neurobiology at HMS. He is faculty both in the department of Neurobiology at Harvard Medical School and in the Harvard Stem Cell Institute. Over his career, Dr. Woolf has received many honors and prizes. In 2020 he was elected a fellow of the American Academy of Arts and Sciences and was awarded a Doctoris Honoris Causa from the University of Lausanne, Switzerland. In addition, he received a Gill Distinguished Scientist award, the Reeve-Irvine medal in 2017, and in 2015, the Kerr award from the American Pain Society. Dr. Woolf was appointed to the Board of Scientific Councilors of the National Institute of Neurological Diseases and Stroke from 2015 to 2019 and is currently a member of the NIH HEAL Partnership Committee for the development of new treatments for pain and addiction. He has published over 300 research papers on molecular, cellular, and systems neurobiology and has more than 30 issued patents. His research is devoted to investigating how the functional, chemical, and structural plasticity of neurons is involved in both the normal adaptive functions of the nervous system and in maladaptive changes that contribute to neurological diseases. His research focuses on pain, regeneration, neurodegeneration, and the exploitation of stem cell-derived neurons to model disease and drug screening.